The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

Cell therapies are the future of healthcare, why are we struggling to make them at scale?

The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales ...